The association between diabetes related medical costs and glycemic control: A retrospective analysis

Cost Effectiveness and Resource Allocation

Volumn 4, Issue , 2006, Pages

  Oglesby, Alan K ^a   Secnik, Kristina ^a   Barron, John ^b   Al Zakwani, Ibrahim ^b   Lage, Maureen J ^c  

^a ELI LILLY AND COMPANY   (United States)

^b HEALTHCORE INC   (United States)

^c HealthMetrics Outcomes Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID DERIVATIVE; BIGUANIDE; GLUCOSE 1 PHOSPHATE; GLUCOSE DERIVATIVE; HEMOGLOBIN A1C; INSULIN; INSULIN SENSITIZING AGENT; MEGLITINIDE; ORAL ANTIDIABETIC AGENT; SULFONYLUREA;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST UTILITY ANALYSIS; DATA ANALYSIS; DATA BASE; DRUG COST; FEMALE; FOLLOW UP; GLYCEMIC CONTROL; HEALTH CARE COST; HEALTH CARE PLANNING; HUMAN; INDIVIDUALITY; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRESCRIPTION; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; STATISTICAL MODEL; STATISTICAL SIGNIFICANCE;

EID: 33144490068     PISSN: 14787547     EISSN: None     Source Type: Journal    
DOI: 10.1186/1478-7547-4-1     Document Type: Article

References (25)

1. World Health Organization: [http://www.who.int/mediacentre/factsheets/ fs236/en].
2. Davis B, Barnard T: Defeating Diabetes Summertown TN: Healthy Living Publications; 2003.
3. Centers for Disease Control and Prevention: Prevalence and incidence. In 1999 Diabetes Surveillance Report Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2004.
4. Cowie CC, Rust KF, Byrd-Holt D, Eberhardt MS, Saydah S, Geiss LS, Engelgau MM, Ford ES, Gregg EW: Prevalence of diabetes and impaired fasting glucose in adults - United States, 1999-2000. MMWR 2003, 52:833-837.
5. Hogan P, Dall T, Nikolov P, American iabetes Association: Economic costs of diabetes mellitus in the US in 2002. Diabetes Care 2003, 26:917-32.
6. Gregg EW, Engelgau MM, Narayan V: Complications of diabetes in elderly people. BMJ 2002, 325:916-917.
7. Hart HE, Bilo HJ, Redekop WK, Stolk RP, Assink JH, Meyboom-de Jon B: Quality of life of patients with type I diabetes mellitus. Qual Life Res 2003, 12:1089-97.
8. Coffey JT, Brandle M, Zhao H, Marriott D, Burke R, Tabaei BP, Engelgau MM, Kaplan RM, Herman WH: Valuing health-related quality of life in diabetes. Diabetes Care 2002, 25:2238-43.
9. U.K. Prospective Diabetes Study Group: Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). Diabetes Care 1999, 22:1125-36.
10. Stratton IM, Adler AI, Neil HAW, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes: prospective observational study. BMJ 2000, 321:405-412.
11. American Diabetes Association: Standards of medical care for patients with diabetes mellitus. Diabetes Care 2003, 26:S33-50.
12. National Center for Quality Assurance: Health Employer Data and Information Set. HEDIS® Technical Report. 2004, 2: [http://www.ncqa.org/Programs/HEDIS/HEDIS04Update_Final.pdf].
13. National Institute for Clinical Excellence: Management of Type 2 diabetes - renal disease, prevention, and early management (html). [http://www.nice.org.uk/page.aspx?0=27964].
14. European diabetes policy group 1999: A desktop guide to type 2 diabetes mellitus. Diabetic Medicine 1999, 16:716-30.
15. Menzin J, Langley-Hawthorne C, Friedman M, Boulanger L, Cavanaugh R: Potential short-term economic benefits of improved glycemic control: a managed care perspective. Diabetes Care 2001, 24:51-55.
16. Wagner EH, Sandhu N, Newton KIM, McCulloch DK, Ramsey SD, Grothaus LC: Effect of improved glycemic control on health care costs and utilization. JAMA 2001, 285:182-189.
17. Gilmer TP, O'Connor PJ, Manning WG, Rush WA: The cost to health plans of poor glycemic control. Diabetes Care 1997, 20:735-744.
18. STATA User's Guide College Station TX: Stata Press; 2003.
19. Hawkins D, Bradberry JC, Cziraky MJ, Talbert RL, Bartles DW, Cerveny JD: National pharmacy cardiovascular council treatment guidelines for the management of type 2 diabetes mellitus: toward better patient outcomes and new roles for pharmacists. Pharmacotherapy 2002, 22:236-44.
20. Le Roith D: Current therapeutic algorithms for type 2 diabetes. Clin Cornerstone 2001, 4:38-49.
21. Scheen AJ, Fefebvre PJ: Oral antidiabetic agents: a guide to selection. Drugs 1998, 55:225-36.
22. DeWitt DE, Dugdale DC: Using new insulin strategies in the outpatient treatment of diabetes. Clinical Applications. JAMA 2003, 289:2265-9.
23. Hertz RP, Unger AN, Lustik MB: Adherence with pharmacotherapy for Type 2 diabetes: A retrospective cohort study of adults with employer-sponsored health insurance. Clinical Therapeutics 2005, 27:1064-1073.
24. Rajagopalan R, Rosenson RS, Fernandes AW, Khan M, Murray FT: Association between congestive heart failure and hospitalization in patients with type 2 diabetes mellitus receiving treatment with insulin or pioglitazone: A retrospective data analysis. Clinical Therapeutics 2004, 26:1400-1410.
25. Vanderpoel DR, Hussein MA, Watson-Heidari T, Perry A: Adherence to a fixed-dose combination of rosiglitazone maleate/metformin hydrochloride in subjects with type 2 diabetes mellitus: A retrospective database analysis. Clinical Therapeutics 2004, 26:2066-2075.